ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2156 entries already.
As a late-stage investor focusing on the European bioeconomy, the ECBF is carefully assessing the maturity of any technology, but more important than maturity is the ability to reach commercial scale. What governs that scale-up, and how do we assess it? What role does the TRL score play, and what key questions do we ask? An excerpt into a framework.
CB21 Pharma Ltd announces that it entered a global strategic collaboration to combine
its leading expertise and clinical research program in phytocannabinoids with world-class
pharmaceutical strategic consulting and business development services of NorthStar Corporate Finance Ltd and Kru?ger Beteiligungs GmbH, forming a new company called CB21 R&D.
The 24th edition is showcasing almost 150 companies with detailed portraits in English on 300 colored pages: small and medium-sized companies with a focus on research and development as well as successful global players. The guide is the international business card of Germanys biotechnology industry.
German Neotiv GmbH hat closed a €10m seed financing to speed-up product launch of its early diagnosis app for Alzheimer’s disease
BioFIT is Europe’s leading partnering event in Life Sciences for tech transfer, early-stage innovation deals and pre-seed, seed and Series A investment, receiving each year more than 1,000 delegates from over 35 countries. For its 11th edition, BioFIT will be held in Strasbourg, France on November 29th and 30th, and on a digital format on December 7th and 8th.
Researchers from the University of Linz (Austria) report progress on the way to make electronic devices more sustainable and more recyclable
Takeda, Boehringer Ingelheim and Novartis do it repeatedly. Global players make major investments in their Austrian facilities. Not only multinationals but start-ups and scale-ups such as Apeiron Biologics and ViraTherapeutics benefit from a comprehensive ecosystem – from basic research to production and distribution. The business location agency ABA is the first point of contact for setting up operations in Austria.
Eppendorf Tubes® BioBased reduce the product-specific carbon footprint and support environmental friendly lab workflow.
Antibody developer Memo Therapeutics AG has snaged a R&D partnership with Ono Pharmaceutical Co. Ltd in the immuno-oncology field.
Keeping biologicals at low temperatures is an established and effective way of maintaining their potency. This is critical for many types of medicines, vaccines, reagents, and biological samples, which is the reason why laboratories, hospitals, clinics, pharmacies, and more employ medical-grade refrigerators to protect their samples from ambient conditions.